BIOMAT Database Logo BIOMAT Database Logo

4-demethoxydaunorubicin (idarubicin) in combination with 1-beta-D-arabinofuranosylcytosine in the treatment of relapsed or refractory acute leukemia. 1989

E Berman, and V Raymond, and A Daghestani, and Z A Arlin, and T S Gee, and S Kempin, and C Hancock, and L Williams, and Y W Stevens, and B D Clarkson
Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York.

We conducted a Phase I-II trial of 4-demethoxydaunorubicin (idarubicin, IDR) in combination with 1-beta-D-arabinofuranosylcytosine (ara-C) in 51 patients with relapsed or refractory acute nonlymphocytic leukemia, acute lymphocytic leukemia, or chronic myelogenous leukemia in blast crisis. Only 1 of 12 patients treated at the first dose level (idarubicin, 10 mg/m2/day for 3 days and ara-C, 25 mg/m2 i.v. bolus followed by 200 mg/m2 continuous infusion daily for 5 days) achieved aplasia and complete remission. The dose of idarubicin was subsequently increased to 10 mg/m2/day for 4 days with the ara-C dose held constant. Complete remission incidence for this dose schedule was: 7 of 31 patients with acute nonlymphocytic leukemia, 0 of 5 patients with acute lymphocytic leukemia, 0 of 1 patient with chronic myelogenous leukemia in blast crisis, and 1 of 2 patients with biphenotypic leukemia. Nonhematological toxicity included nausea, vomiting, mucositis, and abnormal liver function tests. Detailed pharmacological studies were performed to determine whether ara-C altered IDR metabolism or that of its main metabolite, 13-hydroxyidarubicinol or IDR clearance. A high degree of variability among patients was apparent and no consistent effect could be demonstrated. In summary, 9 of 37 patients (24%) with relapsed or refractory ANLL, including 1 patient with biphenotypic leukemia, achieved remission. We conclude that idarubicin in combination with ara-C is an active combination in patients with relapsed or refractory leukemia.

UI MeSH Term Description Entries
D007938 Leukemia A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006) Leucocythaemia,Leucocythemia,Leucocythaemias,Leucocythemias,Leukemias
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D003561 Cytarabine A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472) Ara-C,Arabinofuranosylcytosine,Arabinosylcytosine,Cytosine Arabinoside,Aracytidine,Aracytine,Cytarabine Hydrochloride,Cytonal,Cytosar,Cytosar-U,beta-Ara C,Ara C,Arabinoside, Cytosine,Cytosar U,beta Ara C
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

E Berman, and V Raymond, and A Daghestani, and Z A Arlin, and T S Gee, and S Kempin, and C Hancock, and L Williams, and Y W Stevens, and B D Clarkson
4-Demethoxydaunorubicin (idarubicin) in refractory or relapsed acute leukemias.
January 1984, Haematologica,
E Berman, and V Raymond, and A Daghestani, and Z A Arlin, and T S Gee, and S Kempin, and C Hancock, and L Williams, and Y W Stevens, and B D Clarkson
4-Demethoxydaunorubicin (idarubicin) in relapsed and refractory acute myeloid leukemia.
January 1987, Haematology and blood transfusion,
E Berman, and V Raymond, and A Daghestani, and Z A Arlin, and T S Gee, and S Kempin, and C Hancock, and L Williams, and Y W Stevens, and B D Clarkson
4-Demethoxydaunorubicin (Idarubicin) in refractory or relapsed acute leukemias. A pilot study.
April 1985, Cancer,
E Berman, and V Raymond, and A Daghestani, and Z A Arlin, and T S Gee, and S Kempin, and C Hancock, and L Williams, and Y W Stevens, and B D Clarkson
Idarubicin in the treatment of relapsed or refractory acute myeloid leukemia.
October 1987, Cancer treatment reports,
E Berman, and V Raymond, and A Daghestani, and Z A Arlin, and T S Gee, and S Kempin, and C Hancock, and L Williams, and Y W Stevens, and B D Clarkson
Evaluation of a polychemotherapeutic regimen including Idarubicin (4-demethoxydaunorubicin) in relapsed acute lymphocytic leukemia.
January 1986, Haematologica,
E Berman, and V Raymond, and A Daghestani, and Z A Arlin, and T S Gee, and S Kempin, and C Hancock, and L Williams, and Y W Stevens, and B D Clarkson
Idarubicin in combination with intermediate-dose cytarabine in the treatment of refractory or relapsed acute leukemias.
October 1989, European journal of haematology,
E Berman, and V Raymond, and A Daghestani, and Z A Arlin, and T S Gee, and S Kempin, and C Hancock, and L Williams, and Y W Stevens, and B D Clarkson
Phase I trial of Idarubicin (4-demethoxydaunorubicin) in adult acute leukemia.
January 1984, Investigational new drugs,
E Berman, and V Raymond, and A Daghestani, and Z A Arlin, and T S Gee, and S Kempin, and C Hancock, and L Williams, and Y W Stevens, and B D Clarkson
Idarubicin in sequential combination with cytosine arabinoside in the treatment of relapsed and refractory patients with acute non-lymphoblastic leukemia.
July 1987, European journal of cancer & clinical oncology,
E Berman, and V Raymond, and A Daghestani, and Z A Arlin, and T S Gee, and S Kempin, and C Hancock, and L Williams, and Y W Stevens, and B D Clarkson
Treatment of acute myelogenous leukemia in adults with N4-behenoyl-1-beta-D-arabinofuranosylcytosine.
October 1985, Cancer,
E Berman, and V Raymond, and A Daghestani, and Z A Arlin, and T S Gee, and S Kempin, and C Hancock, and L Williams, and Y W Stevens, and B D Clarkson
Cellular pharmacology and optimal therapeutic concentrations of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in leukemic blasts during treatment of refractory leukemia with high-dose 1-beta-D-arabinofuranosylcytosine.
January 1986, Scandinavian journal of haematology. Supplementum,
Copied contents to your clipboard!